Skip to content
10-K

Annual Report

Oncolix, Inc.

0001477932-18-001291

← back to feed
Filed
Mar 14, 2018 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2017 · Mar 14, 2018 104.48M sh
Operating Cash Flow FY 2017 · Dec 31, 2017 −$2.38M
Operating Cash Flow restated FY 2017 · Dec 31, 2016 −$445.27K
Cash And Equivalents FY 2017 · Dec 31, 2017 $494.41K
Cash And Equivalents restated FY 2017 · Dec 31, 2016 $15.26K
Cash And Equivalents FY 2017 · Dec 31, 2015 $274.06K
Stockholders Equity FY 2017 · Dec 31, 2017 −$1.64M
Stockholders Equity restated FY 2017 · Dec 31, 2016 −$2.13M
Stockholders Equity restated FY 2017 · Dec 31, 2015 −$823.11K
Current Liabilities FY 2017 · Dec 31, 2017 $1.26M
Current Liabilities restated FY 2017 · Dec 31, 2016 $1.28M
Total Liabilities FY 2017 · Dec 31, 2017 $2.53M
Total Liabilities restated FY 2017 · Dec 31, 2016 $2.55M
Current Assets FY 2017 · Dec 31, 2017 $889.4K
Current Assets restated FY 2017 · Dec 31, 2016 $382.16K
Total Assets FY 2017 · Dec 31, 2017 $889.4K
Total Assets restated FY 2017 · Dec 31, 2016 $420.84K
Sga Expense FY 2017 · Dec 31, 2017 $1.49M
Sga Expense restated FY 2017 · Dec 31, 2016 $620.84K
Rd Expense FY 2017 · Dec 31, 2017 $462.63K
Rd Expense FY 2017 · Dec 31, 2016 $709.01K
Net Income FY 2017 · Dec 31, 2017 −$3.36M
Net Income restated FY 2017 · Dec 31, 2016 −$1.39M